Timothy Mark Willson

This study characterizes the kinetic mechanism and structural dynamics of Chikungunya virus nsP2 RNA helicase during nucleotide hydrolysis using biochemical and computational methods.

The paper describes the enantioselective resolution of a chemical probe targeting CHIKV nsP2 helicase, showing potent antiviral activity for one enantiomer and low activity for the other.

The paper identifies structure-activity relationships for diarylpyrazole inhibitors of the fungal kinase Yck2, showing improved selectivity and antifungal activity.

This study identifies a first-in-class inhibitor of alphavirus nsP2 helicase activity, showing broad antiviral activity and in vivo efficacy against chikungunya virus.

This paper identifies and optimizes oxaspiropiperidine inhibitors targeting nsP2hel, showing nanomolar antiviral activity against multiple alphaviruses.

This study evaluates the species-dependent metabolism and pharmacokinetics of a covalent nsP2 protease inhibitor, showing rapid clearance in mice but antiviral efficacy, and suggests potential for human dosing.

The paper uses chemoproteomic profiling to identify selective anti-fungal kinase inhibitors targeting C. albicans CK1 homologs.

The paper identifies inhibitors of Chikungunya virus nsP2 ATPase by screening compounds that reduce ATP hydrolysis.

This paper identifies and characterizes RA-0002034, a covalent inhibitor of CHIKV nsP2 protease, showing potent inhibition and selectivity against alphaviruses.

The paper identifies potent covalent inhibitors of Chikungunya nsP2 protease and establishes structure-activity relationships to guide inhibitor design.

The paper curates a database of helicase inhibitors, Heli-SMACC, and tests selected compounds against SARS-CoV-2 NSP13 ATPase, finding twelve inhibitors with dose-response activity.

The paper synthesizes pyrimidoquinoline derivatives as CSNK2A inhibitors with antiviral activity, finding that certain substituents improve potency while maintaining solubility.

The paper compiles an annotated set of 171 small molecule modulators targeting 98 novel AD therapeutic proteins, serving as chemical tools for hypothesis validation.